Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.

Leukemia & lymphoma - 1 Aug 2018

Ma Juan, Dunlap Jennifer, Paliga Aleksandra, Traer Elie, Press Richard, Shen Lisong, Fan Guang

Abstract excerpt

This single institution cohort study of 132 AML patients investigated the clinical implications of co-mutations detected with a 42-gene NGS panel. In the intermediate-risk cytogenetic group, FLT3-ITD is an adverse prognostic indicator only in the presence of a DNMT3A co-mutation, regardless of NPM1 mutation status. In the absence of a concomitant DNMT3A mutation, there was no significant difference in overall...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to DNA (Cytosine-5-)-Methyltransferases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methyltransferase 3A

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid

Share to Neoplasm Recurrence, Local

Share to Nucleophosmin

Share to Tandem Repeat Sequences

Source

Identifiers

PMID: 29165010
DOI: 10.1080/10428194.2017.1397659

Genes

FLT3
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.PMID 29165010Read ↗

Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival.Semantic proximity Read ↗

Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de novo acute myeloid leukemiaSemantic proximity Read ↗

Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients.Semantic proximity Read ↗

Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid LeukemiaSemantic proximity Read ↗

The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations.Semantic proximity Read ↗

Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.Semantic proximity Read ↗

Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutationsSemantic proximity Read ↗

The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AMLSemantic proximity Read ↗

Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.Semantic proximity Read ↗

Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients.Semantic proximity Read ↗

Acute Myeloid Leukemia With Recurrent Genetic Abnormalities Other Than Translocations.Semantic proximity Read ↗

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.